|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosell R, Bivona TG and Karachaliou N:
Genetics and biomarkers in personalisation of lung cancer
treatment. Lancet. 382:720–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gerber DE and Schiller JH: Maintenance
chemotherapy for advanced non-small-cell lung cancer: New life for
an old idea. J Clin Oncol. 31:1009–1020. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brudno JN and Kochenderfer JN: Chimeric
antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol.
15:31–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anagnostou V, Smith KN, Forde PM, Niknafs
N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N,
et al: Evolution of neoantigen landscape during immune checkpoint
blockade in non-small cell lung cancer. Cancer Discov. 7:264–276.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, et al: Cancer immunology. Mutational
landscape determines sensitivity to PD-1 blockade in non-small cell
lung cancer. Science. 348:124–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Erfani N, Mehrabadi SM, Ghayumi MA,
Haghshenas MR, Mojtahedi Z, Ghaderi A and Amani D: Increase of
regulatory T cells in metastatic stage and CTLA-4 over expression
in lymphocytes of patients with non-small cell lung cancer (NSCLC).
Lung Cancer. 77:306–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharpe AH and Pauken KE: The diverse
functions of the PD1 inhibitory pathway. Nat Rev Immunol.
18:153–167. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neelapu SS, Tummala S, Kebriaei P, Wierda
W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et
al: Chimeric antigen receptor T-cell therapy-assessment and
management of toxicities. Nat Rev Clin Oncol. 15:47–62. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ludin A and Zon LI: Cancer immunotherapy:
The dark side of PD-1 receptor inhibition. Nature. 552:41–42. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Torreira E, Louro JA, Pazos I,
González-Polo N, Gil-Carton D, Duran AG, Tosi S, Gallego O, Calvo O
and Fernández-Tornero C: The dynamic assembly of distinct RNA
polymerase I complexes modulates rDNA transcription. Elife. 6(pii):
e208322017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Engel C, Gubbey T, Neyer S, Sainsbury S,
Oberthuer C, Baejen C, Bernecky C and Cramer P: Structural basis of
RNA polymerase i transcription initiation. Cell. 169:120–131.e22.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Andersen JS, Lam YW, Leung AK, Ong SE,
Lyon CE, Lamond AI and Mann M: Nucleolar proteome dynamics. Nature.
433:77–83. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seither P and Grummt I: Molecular cloning
of RPA2, the gene encoding the second largest subunit of mouse RNA
polymerase I. Genomics. 37:135–139. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chan JC, Hannan KM, Riddell K, Ng PY, Peck
A, Lee RS, Hung S, Astle MV, Bywater M, Wall M, et al: AKT promotes
rRNA synthesis and cooperates with c-MYC to stimulate ribosome
biogenesis in cancer. Sci Signal. 4:ra562011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Drygin D, Rice WG and Grummt I: The RNA
polymerase I transcription machinery: An emerging target for the
treatment of cancer. Annu Rev Pharmacol Toxicol. 50:131–156. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Williamson D, Lu YJ, Fang C,
Pritchard-Jones K and Shipley J: Nascent pre-rRNA overexpression
correlates with an adverse prognosis in alveolar rhabdomyosarcoma.
Genes Chromosomes Cancer. 45:839–845. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sanchez-Palencia A, Gomez-Morales M,
Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R and Fárez-Vidal ME:
Gene expression profiling reveals novel biomarkers in nonsmall cell
lung cancer. Int J Cancer. 129:355–364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nabzdyk CS, Chun M, Pradhan L and Logerfo
FW: High throughput RNAi assay optimization using adherent cell
cytometry. J Transl Med. 9:482011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43((Database Issue)): D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Su G, Morris JH, Demchak B and Bader GD:
Biological network exploration with Cytoscape 3. Curr Protoc
Bioinformatics. 47:8 13 11–24. 2014. View Article : Google Scholar
|
|
27
|
White RJ: RNA polymerases I and III,
non-coding RNAs and cancer. Trends Genet. 24:622–629. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cornelison R, Dobbin ZC, Katre AA, Jeong
DH, Zhang Y, Chen D, Petrova Y, Llaneza DC, Steg AD, Parsons L, et
al: Targeting RNA-polymerase I in both chemosensitive and
chemoresistant populations in epithelial ovarian cancer. Clin
Cancer Res. 23:6529–6540. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bywater MJ, Poortinga G, Sanij E, Hein N,
Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, et al:
Inhibition of RNA polymerase I as a therapeutic strategy to promote
cancer-specific activation of p53. Cancer Cell. 22:51–65. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Drygin D, Siddiqui-Jain A, O'Brien S,
Schwaebe M, Lin A, Bliesath J, Ho CB, Proffitt C, Trent K, Whitten
JP, et al: Anticancer activity of CX-3543: A direct inhibitor of
rRNA biogenesis. Cancer Res. 69:7653–7661. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ruggero D: Revisiting the nucleolus: From
marker to dynamic integrator of cancer signaling. Sci Signal.
5:pe382012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peltonen K, Colis L, Liu H, Trivedi R,
Moubarek MS, Moore HM, Bai B, Rudek MA, Bieberich CJ and Laiho M: A
targeting modality for destruction of RNA polymerase I that
possesses anticancer activity. Cancer Cell. 25:77–90. 2014.
View Article : Google Scholar : PubMed/NCBI
|
